United Therapeutics $UTHR
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.0 months). See all sponsors →
Open United Therapeutics on the live radar map → 📅 $UTHR readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Ralinepag NCT03683186 |
P3 | Enrolling by invitation | PAH; Pulmonary Hypertension | 1000 | 2026-12 (+27 mo) |
| Inhaled Treprostinil NCT05943535 |
P3 | Recruiting | Progressive Pulmonary Fibrosis; Interstitial Lung Disease | 698 | 2027-11 |
| SUMMIT 201 NCT07923591 |
P2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | 2028-05 |
| EXPAND NCT06878560 |
P1/2 | Recruiting | ESRD (End-Stage Renal Disease); Kidney Transplantation | 50 | 2028-10 (+4 mo) |
| EXTEND NCT07224763 |
P1/2 | Recruiting | ESRD (End-Stage Renal Disease); Kidney Transplantation | 50 | 2029-11 (+8 mo) |
| TETON-OLE NCT04905693 |
P3 | Enrolling by invitation | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | 1850 | 2029-12 (+67 mo) |
| SUMMIT OLE NCT07923526 |
P2/3 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 400 | 2034-09 |